Targeting PPARβ/δ for the treatment of type 2 diabetes mellitus

Author： Salvadó Laia   Serrano-Marco Lucía   Barroso Emma   Palomer Xavier   Vázquez-Carrera Manuel  

Publisher： Informa Healthcare

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.16, Iss.2, 2012-02, pp. : 209-223

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

PPAR-β/δ agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home

By Billin Andrew N  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 10, 2008-10 ,pp. : 1465-1471

Informa Healthcare

Access to resources Recommend Favorite

Orlistat: In the Prevention and Treatment of Type 2 Diabetes Mellitus

By Keating G.M.   Jarvis B.  

Drugs, Vol. 61, Iss. 14, 2001-01 ,pp. : 2107-2119

Adis International

Access to resources Recommend Favorite

Meglitinide Analogues in the Treatment of Type 2 Diabetes Mellitus

By Landgraf R.  

Drugs & Aging, Vol. 17, Iss. 5, 2000-11 ,pp. : 411-425

Adis International

Access to resources Recommend Favorite

Orlistat in the treatment of Type 2 diabetes mellitus

By Jneidi Muna   Kelley David E  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 5, 2002-05 ,pp. : 599-605

Informa Healthcare

Access to resources Recommend Favorite

Vildagliptin in the treatment of type 2 diabetes mellitus

By Stamataros George   Schneider Stephen H  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 12, 2011-08 ,pp. : 1967-1973

Informa Healthcare

Access to resources Recommend Favorite